Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Irbesartan/Hydrochlorothiazide Teva
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-211962 · Präparat HOS-154792
Antigout medicinal products
Dosage adjustments of antigout medicinal products may be necessary as hydrochlorothiazide may raise the
level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary.
Co-administration of thiazide diuretics may increase the incidence of hypersensitivity reactions to
allopurinol;
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfinpyrazone (HOS-089177) allopurinol (HOS-089178) probenecid (HOS-085208) uric acid (HOS-089176)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T17:46:00Z · SHA-256 d153807aa78b933b85a74033d8ce9ad79fcd03f761c66d536fff8befc9ae2c26 · Passage 3338e1e1199c03c543c528129b326adce35930b0d581fab44a592ae8f7b3e96e · Zeichen 5817–6156 im Abschnitt
Wechselwirkungen · Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/75 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-212249 · Präparat HOS-154856
Uricosurics (benzbromarone, probenecid, sulfinpyrazone)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfinpyrazone (HOS-089177) probenecid (HOS-085208) benzbromarone (HOS-212250)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2019-11-13T14:36:00Z · SHA-256 fdf7b1939833e55bbc6a1c8732c66c147ac4404b0347a1c2e50406556ee7b8c0 · Passage fd224c673be620cc583f148581d7f4af1c8af64b63002aad9174554f706267b3 · Zeichen 6802–6857 im Abschnitt
Wechselwirkungen · Copalia HCT
Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 5 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–11
HOS-122667 · Präparat HOS-095555
9
Dantrolene (infusion) In animals, lethal ventricular fibrillation and
cardiovascular collapse are observed in association with
hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is
recommended that the co-administration of calcium
channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the
management of malignant hyperthermia.
Tacrolimus There is a risk of increased tacrolimus blood levels when
co-administered with amlodipine. In order to avoid
toxicity of tacrolimus, administration of amlodipine in a
patient treated with tacrolimus requires monitoring of
tacrolimus blood levels and dose adjustment of tacrolimus
when appropriate.
Valsartan Non-steroidal anti- NSAIDS can attenuate the antihypertensive effect of both
and HCT inflammatory drugs angiotensin II antagonists and hydrochlorothiazide when
(NSAIDs), including administered simultaneously. Furthermore, concomitant
selective use of Copalia HCT and NSAIDs may lead to worsening
cyclooxygenase-2 of renal function and an increase in serum potassium.
inhibitors (COX-2 Therefore, monitoring of renal function at the beginning of
inhibitors), the treatment is recommended, as well as adequate
acetylsalicylic acid hydration of the patient.
(>3 g/day), and non-
selective NSAIDs
Valsartan Inhibitors of the uptake The results of an in vitro study with human liver tissue
transporter (rifampicin, indicate that valsartan is a substrate of the hepatic uptake
ciclosporin) or efflux transporter OATP1B1 and of the hepatic efflux transporter
transporter (ritonavir) MRP2. Co-administration of inhibitors of the uptake
transporter (rifampicin, ciclosporin) or efflux transporter
(ritonavir) may increase the systemic exposure to
valsartan.
HCT Alcohol, barbiturates Concomitant administration of thiazide diuretics with
or narcotics substances that also have a blood pressure lowering effect
(e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic
hypotension.
Amantadine Thiazides, including hydrochlorothiazide, may increase
the risk of adverse reactions caused by amantadine.
Anticholinergic agents The bioavailability of thiazide-type diuretics may be
and other medicinal increased by anticholinergic agents (e.g. atropine,
products affecting biperiden), apparently due to a decrease in gastrointestinal
gastric motility motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride
may decrease the bioavailability of thiazide-type diuretics.
Antidiabetic agents Thiazides may alter glucose tolerance. Dose adjustment of
(e.g. insulin and oral the antidiabetic medicinal product may be necessary.
antidiabetic agents)
− Metformin Metformin should be used with caution because of the risk
of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.
Beta blockers and Concomitant use of thiazide diuretics, including
diazoxide hydrochlorothiazide, with beta blockers may increase the
risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic
effect of diazoxide.
Ciclosporin Concomitant treatment with ciclosporin may increase the
risk of hyperuricaemia and gout-type complications.
10
Cytotoxic agents Thiazides, including hydrochlorothiazide, may reduce the
renal excretion of cytotoxic agents (e.g.
cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Digitalis glycosides Thiazide-induced hypokalaemia or hypomagnesaemia may
occur as undesirable effects, favouring the onset of
digitalis-induced cardiac arrhythmias.
Iodine contrasting In case of diuretic-induced dehydration, there is an
agents increased risk of acute renal failure, especially with high
doses of iodine products. Patients should be re-hydrated
before the administration.
Ion exchange resins Absorption of thiazide diuretics, including
hydrochlorothiazide, is decreased by cholestyramine or
colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of
hydrochlorothiazide and resin such that
hydrochlorothiazide is administered at least 4 hours before
or 4-6 hours after the administration of resins would
potentially minimise the interaction.
Medicinal products The hypokalaemic effect of hydrochlorothiazide may be
affecting serum increased by concomitant administration of kaliuretic
potassium level diuretics, corticosteroids, laxatives, adrenocorticotropic
hormone (ACTH), amphotericin, carbenoxolone,
penicillin G and salicylic acid derivatives or
antiarrhythmics. If these medicinal products are to be
prescribed with the amlodipine /valsartan
/hydrochlorothiazide combination, monitoring of
potassium plasma levels is advised.
Medicinal products The hyponatraemic effect of diuretics may be intensified
affecting serum sodium by concomitant administration of medicinal products such
level as antidepressants, antipsychotics, antiepileptics, etc.
Caution is indicated in long-term administration of these
medicinal products.
Medicinal products that Due to the risk of hypokalaemia, hydrochlorothiazide
could induce torsades should be administered with caution when associated with
de pointes medicinal products that could induce torsades de pointes,
in particular Class Ia and Class III antiarrhythmics and
some antipsychotics.
Medicinal products Dose adjustment of uricosuric medicinal products may be
used in the treatment of necessary as hydrochlorothiazide may raise the level of
gout (probenecid, serum uric acid. Increase of dose of probenecid or
sulfinpyrazone and sulfinpyrazone may be necessary.
allopurinol) Co-administration of thiazide diuretics, including
hydrochlorothiazide, may increase the incidence of
hypersensitivity reactions to allopurinol.
Methyldopa There have been isolated reports of haemolytic anaemia
occurring with concomitant use of hydrochlorothiazide
and methyldopa.
Non-depolarising Thiazides, including hydrochlorothiazide, potentiate the
skeletal muscle action of curare derivatives.
relaxants (e.g.
tubocurarine)
Other anti-hypertensive Thiazides potentiate the antihypertensive action of other
medicinal products antihypertensive drugs (e.g. guanethidine, methyldopa,
beta-blockers, vasodilators, calcium channel blockers,
ACE inhibitors, ARBs and Direct Renin Inhibitors
[DRIs]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) sulfinpyrazone (HOS-089177) sodium (HOS-109681) cisapride (HOS-085610) allopurinol (HOS-089178) diazoxide (HOS-088588) colestipol (HOS-089168) dantrolene (HOS-109261) atropine (HOS-089182) glucose (HOS-088412) amphotericin (HOS-088524) salicylic acid (HOS-088803) calcium (HOS-085615) lead (HOS-085592) amantadine (HOS-086615) biperiden (HOS-085953) probenecid (HOS-085208) uric acid (HOS-089176) tacrolimus (HOS-085202) cyclophosphamide (HOS-084539) guanethidine (HOS-088596) ritonavir (HOS-084521) potassium (HOS-086929) methyldopa (HOS-086564) penicillin G (HOS-121627) tubocurarine (HOS-089174) carbenoxolone (HOS-089156) iodine (HOS-087479) metformin (HOS-091032) methotrexate (HOS-087522) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T11:21:00Z · SHA-256 230f24622c23683c6a46653c5bf6b1c68bc72aa3359d9f8eed8a17a080938906 · Passage 131d80a8b0eaa19356ee9d14064b9ff9cbc55b6c5f27c3883f1f818096746a3b · Zeichen 4434–13492 im Abschnitt
Wechselwirkungen · Dafiro HCT
Dafiro HCT 5 mg/160 mg/12.5 mg film-coated tablets Dafiro HCT 10 mg/160 mg/12.5 mg film-coated tablets Dafiro HCT 5 mg/160 mg/25 mg film-coated tablets Dafiro HCT 10 mg/160 mg/25 mg film-coated tablets Dafiro HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–11
HOS-122720 · Präparat HOS-095563
9
Dantrolene (infusion) In animals, lethal ventricular fibrillation and
cardiovascular collapse are observed in association with
hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is
recommended that the co-administration of calcium
channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the
management of malignant hyperthermia.
Tacrolimus There is a risk of increased tacrolimus blood levels when
co-administered with amlodipine. In order to avoid
toxicity of tacrolimus, administration of amlodipine in a
patient treated with tacrolimus requires monitoring of
tacrolimus blood levels and dose adjustment of tacrolimus
when appropriate.
Valsartan Non-steroidal anti- NSAIDS can attenuate the antihypertensive effect of both
and HCT inflammatory drugs angiotensin II antagonists and hydrochlorothiazide when
(NSAIDs), including administered simultaneously. Furthermore, concomitant
selective use of Dafiro HCT and NSAIDs may lead to worsening of
cyclooxygenase-2 renal function and an increase in serum potassium.
inhibitors (COX-2 Therefore, monitoring of renal function at the beginning of
inhibitors), the treatment is recommended, as well as adequate
acetylsalicylic acid hydration of the patient.
(>3 g/day), and non-
selective NSAIDs
Valsartan Inhibitors of the uptake The results of an in vitro study with human liver tissue
transporter (rifampicin, indicate that valsartan is a substrate of the hepatic uptake
ciclosporin) or efflux transporter OATP1B1 and of the hepatic efflux transporter
transporter (ritonavir) MRP2. Co-administration of inhibitors of the uptake
transporter (rifampicin, ciclosporin) or efflux transporter
(ritonavir) may increase the systemic exposure to
valsartan.
HCT Alcohol, barbiturates Concomitant administration of thiazide diuretics with
or narcotics substances that also have a blood pressure lowering effect
(e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic
hypotension.
Amantadine Thiazides, including hydrochlorothiazide, may increase
the risk of adverse reactions caused by amantadine.
Anticholinergic agents The bioavailability of thiazide-type diuretics may be
and other medicinal increased by anticholinergic agents (e.g. atropine,
products affecting biperiden), apparently due to a decrease in gastrointestinal
gastric motility motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride
may decrease the bioavailability of thiazide-type diuretics.
Antidiabetic agents Thiazides may alter glucose tolerance. Dose adjustment of
(e.g. insulin and oral the antidiabetic medicinal product may be necessary.
antidiabetic agents)
− Metformin Metformin should be used with caution because of the risk
of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.
Beta blockers and Concomitant use of thiazide diuretics, including
diazoxide hydrochlorothiazide, with beta blockers may increase the
risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic
effect of diazoxide.
Ciclosporin Concomitant treatment with ciclosporin may increase the
risk of hyperuricaemia and gout-type complications.
10
Cytotoxic agents Thiazides, including hydrochlorothiazide, may reduce the
renal excretion of cytotoxic agents (e.g.
cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Digitalis glycosides Thiazide-induced hypokalaemia or hypomagnesaemia may
occur as undesirable effects, favouring the onset of
digitalis-induced cardiac arrhythmias.
Iodine contrasting In case of diuretic-induced dehydration, there is an
agents increased risk of acute renal failure, especially with high
doses of iodine products. Patients should be re-hydrated
before the administration.
Ion exchange resins Absorption of thiazide diuretics, including
hydrochlorothiazide, is decreased by cholestyramine or
colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of
hydrochlorothiazide and resin such that
hydrochlorothiazide is administered at least 4 hours before
or 4-6 hours after the administration of resins would
potentially minimise the interaction.
Medicinal products The hypokalaemic effect of hydrochlorothiazide may be
affecting serum increased by concomitant administration of kaliuretic
potassium level diuretics, corticosteroids, laxatives, adrenocorticotropic
hormone (ACTH), amphotericin, carbenoxolone,
penicillin G and salicylic acid derivatives or
antiarrhythmics. If these medicinal products are to be
prescribed with the amlodipine /valsartan
/hydrochlorothiazide combination, monitoring of
potassium plasma levels is advised.
Medicinal products The hyponatraemic effect of diuretics may be intensified
affecting serum sodium by concomitant administration of medicinal products such
level as antidepressants, antipsychotics, antiepileptics, etc.
Caution is indicated in long-term administration of these
medicinal products.
Medicinal products that Due to the risk of hypokalaemia, hydrochlorothiazide
could induce torsades should be administered with caution when associated with
de pointes medicinal products that could induce torsades de pointes,
in particular Class Ia and Class III antiarrhythmics and
some antipsychotics.
Medicinal products Dose adjustment of uricosuric medicinal products may be
used in the treatment of necessary as hydrochlorothiazide may raise the level of
gout (probenecid, serum uric acid. Increase of dose of probenecid or
sulfinpyrazone and sulfinpyrazone may be necessary.
allopurinol) Co-administration of thiazide diuretics, including
hydrochlorothiazide, may increase the incidence of
hypersensitivity reactions to allopurinol.
Methyldopa There have been isolated reports of haemolytic anaemia
occurring with concomitant use of hydrochlorothiazide
and methyldopa.
Non-depolarising Thiazides, including hydrochlorothiazide, potentiate the
skeletal muscle action of curare derivatives.
relaxants (e.g.
tubocurarine)
Other anti-hypertensive Thiazides potentiate the antihypertensive action of other
medicinal products antihypertensive drugs (e.g. guanethidine, methyldopa,
beta-blockers, vasodilators, calcium channel blockers,
ACE inhibitors, ARBs and Direct Renin Inhibitors
[DRIs]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) sulfinpyrazone (HOS-089177) sodium (HOS-109681) cisapride (HOS-085610) allopurinol (HOS-089178) diazoxide (HOS-088588) colestipol (HOS-089168) dantrolene (HOS-109261) atropine (HOS-089182) glucose (HOS-088412) amphotericin (HOS-088524) salicylic acid (HOS-088803) calcium (HOS-085615) lead (HOS-085592) amantadine (HOS-086615) biperiden (HOS-085953) probenecid (HOS-085208) uric acid (HOS-089176) tacrolimus (HOS-085202) cyclophosphamide (HOS-084539) guanethidine (HOS-088596) ritonavir (HOS-084521) potassium (HOS-086929) methyldopa (HOS-086564) penicillin G (HOS-121627) tubocurarine (HOS-089174) carbenoxolone (HOS-089156) iodine (HOS-087479) metformin (HOS-091032) methotrexate (HOS-087522) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T17:50:00Z · SHA-256 ac895b922284b71e7c5c23e23c9993c138af1676fdc3c53bcfaa54fe9f7593a7 · Passage 97d44e9311b10ee812c39d023fdb8dcc2cc4eb2fbbe2ddb1ce622654982ed958 · Zeichen 4412–13469 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-124391 · Präparat HOS-095863
There is limited experience of co-administration with other platelet aggregation inhibitors (such as
GPIIb/IIIa receptor antagonists, dipyridamole, dextran or sulfinpyrazone) or thrombolytic agents. As
such agents increase the bleeding risk, co-administration of these medicinal products with apixaban is
not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfinpyrazone (HOS-089177) dextran (HOS-118654) dipyridamole (HOS-088796)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 0c29d1bc53ab0c737c51fea59e28c3c66d7ccfdd1b7116a8c3a9c536f51fbdb2 · Zeichen 4546–4885 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 46
HOS-124445 · Präparat HOS-095863
There is limited experience of co-administration with other platelet aggregation inhibitors (such as
GPIIb/IIIa receptor antagonists, dipyridamole, dextran or sulfinpyrazone) or thrombolytic agents. As
such agents increase the bleeding risk, co-administration of these medicinal products with apixaban is
not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfinpyrazone (HOS-089177) dextran (HOS-118654) dipyridamole (HOS-088796)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 0c29d1bc53ab0c737c51fea59e28c3c66d7ccfdd1b7116a8c3a9c536f51fbdb2 · Zeichen 4530–4869 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 0.15 mg granules in capsules for opening · Abschnitt 4.5 · PDF-Seite 75
HOS-124496 · Präparat HOS-095863
There is limited experience of co-administration with other platelet aggregation inhibitors (such as
GPIIb/IIIa receptor antagonists, dipyridamole, dextran or sulfinpyrazone) or thrombolytic agents. As
such agents increase the bleeding risk, co-administration of these medicinal products with apixaban is
not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfinpyrazone (HOS-089177) dextran (HOS-118654) dipyridamole (HOS-088796)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 0c29d1bc53ab0c737c51fea59e28c3c66d7ccfdd1b7116a8c3a9c536f51fbdb2 · Zeichen 4758–5097 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 0.5 mg coated granule in sachet Eliquis 1.5 mg coated granules in sachet Eliquis 2 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 98
HOS-124547 · Präparat HOS-095863
There is limited experience of co-administration with other platelet aggregation inhibitors (such as
GPIIb/IIIa receptor antagonists, dipyridamole, dextran or sulfinpyrazone) or thrombolytic agents. As
such agents increase the bleeding risk, co-administration of these medicinal products with apixaban is
not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfinpyrazone (HOS-089177) dextran (HOS-118654) dipyridamole (HOS-088796)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 0c29d1bc53ab0c737c51fea59e28c3c66d7ccfdd1b7116a8c3a9c536f51fbdb2 · Zeichen 4769–5108 im Abschnitt
Wechselwirkungen · Ifirmacombi
Ifirmacombi 150 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-125162 · Präparat HOS-096013
Antigout medicinal products: dosage adjustments of antigout medicinal products may be necessary as
hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or
sulfinpyrazone may be necessary. Co-administration of thiazide diuretics may increase the incidence
of hypersensitivity reactions to allopurinol;
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfinpyrazone (HOS-089177) allopurinol (HOS-089178) probenecid (HOS-085208) uric acid (HOS-089176)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T11:57:00Z · SHA-256 de9ed4436066d5e17ee66d54836788a39065e3bc0f0ec088c02563c1958dcb02 · Passage b67fee1047e0a008736a25d6463e56b9b87f17e861378799b899458f514e0c7f · Zeichen 6170–6510 im Abschnitt
Wechselwirkungen · Apixaban Accord
Apixaban Accord 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-146634 · Präparat HOS-099542
There is limited experience of co-administration with other platelet aggregation inhibitors (such as
GPIIb/IIIa receptor antagonists, dipyridamole, dextran or sulfinpyrazone) or thrombolytic agents. As
such agents increase the bleeding risk, co-administration of these medicinal products with apixaban is
not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfinpyrazone (HOS-089177) dextran (HOS-118654) dipyridamole (HOS-088796)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T13:45:00Z · SHA-256 d61ca619dbc3cc41b936fd00150a7483792c8b53e4c986c4c86af1cceab6e2ab · Passage 0c29d1bc53ab0c737c51fea59e28c3c66d7ccfdd1b7116a8c3a9c536f51fbdb2 · Zeichen 4542–4881 im Abschnitt
Wechselwirkungen · Apixaban Accord
Apixaban Accord 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 44
HOS-146681 · Präparat HOS-099542
There is limited experience of co-administration with other platelet aggregation inhibitors (such as
GPIIb/IIIa receptor antagonists, dipyridamole, dextran or sulfinpyrazone) or thrombolytic agents. As
such agents increase the bleeding risk, co-administration of these medicinal products with apixaban is
not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfinpyrazone (HOS-089177) dextran (HOS-118654) dipyridamole (HOS-088796)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T13:45:00Z · SHA-256 d61ca619dbc3cc41b936fd00150a7483792c8b53e4c986c4c86af1cceab6e2ab · Passage 0c29d1bc53ab0c737c51fea59e28c3c66d7ccfdd1b7116a8c3a9c536f51fbdb2 · Zeichen 4470–4809 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.